- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 231/12
Total number of patents in this class: 1989
10-year publication summary
|
159
|
166
|
151
|
164
|
122
|
147
|
128
|
91
|
106
|
54
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4742 |
45 |
| Bayer Cropscience AG | 1844 |
40 |
| Takeda Pharmaceutical Company Limited | 2712 |
40 |
| Epizyme, Inc. | 360 |
32 |
| Arena Pharmaceuticals, Inc. | 344 |
28 |
| Novartis AG | 10262 |
27 |
| University of Southern California | 2132 |
22 |
| Boehringer Ingelheim International GmbH | 4493 |
19 |
| Corteva Agriscience LLC | 2648 |
19 |
| BASF SE | 21303 |
18 |
| Janssen Pharmaceutica N.V. | 3168 |
16 |
| Bayer Pharma AG | 1014 |
15 |
| Sumitomo Chemical Company, Limited | 9016 |
15 |
| Merck Sharp & Dohme LLC | 3734 |
15 |
| F. Hoffmann-La Roche AG | 7837 |
14 |
| The Regents of the University of California | 20745 |
14 |
| E. I. du Pont de Nemours and Company | 3534 |
14 |
| The Board of Trustees of the Leland Stanford Junior University | 6653 |
14 |
| FMC Corporation | 807 |
14 |
| Hoffmann-La Roche Inc. | 3793 |
12 |
| Other owners | 1556 |